^
Association details:
| Biomarker: | PD-L1 overexpression + CD163 underexpression |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Imfinzi (durvalumab) (PD-L1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
5466 / 16 - Functional status of tumor-associated macrophages impacts clinical outcome of durvalumab in patients with advanced NSCLC as revealed by proteomics mass spectrometry
Published date:
03/15/2023
Excerpt:
Pre-treatment tumor samples from 66 patients with advanced NSCLC patients enrolled in durvalumab nonrandomized phase 1/2 trial....patients with PD-L1 TC ≥50% and low CD163 expression derive greater OS benefit (13.4 months mOS) than those with high CD163 expression (5 months mOS) or with PD-L1 TC <50% regardless of level of CD163 expression (4.1-7.4 months mOS)….
